RxDoctor Payments Data

Jasleen Salwan, MD

Internal Medicine · Baltimore, MDNPI 1396192431

Payments from drug & device makers

$1,510in general payments, 2019–2025

Across 70 payments — averaging $21.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$591
  • Amgen$132
  • Bristol Myers Squibb$100
  • AbbVie$82
  • Seqirus USA Inc$71
  • Dexcom, Inc.$60
  • plus $475 from 15 others

What the payments were for

  • Food & beverage$1,510100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,510 in reported general payments places this provider in the 75th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$235,532
Medicare patients
407
Services billed
3,928

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OdefseyEmtricitab/Rilpiviri/Tenof Ala11$46,391
RybelsusSemaglutide18$37,103
EliquisApixaban22$24,604
FarxigaDapagliflozin Propanediol13$19,681
JardianceEmpagliflozin12$17,825
OzempicSemaglutide13$15,589
Rosuvastatin Calcium181$4,783
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl20$2,102
Atorvastatin Calcium118$1,363
Losartan Potassium68$1,216
Olmesartan Medoxomil26$1,136
Ezetimibe21$1,135
Amlodipine Besylate134$971
Metformin Hcl ErMetformin Hcl46$955
Valsartan12$780

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$591$52,69231 claims
PfizerEliquis$15$24,60422 claims
AstraZenecaFarxiga$27$19,68113 claims
Boehringer IngelheimJardiance$36$17,82512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →